Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Research studies have shown a strong association between cancer and blood clots in the veins
(also known as deep vein thrombosis). These blood clots can flow to the lungs (pulmonary
embolism) which in severe cases may be life threatening. Studies have demonstrated that
increases in microparticles may contribute to the development of deep vein thrombosis in
cancer patients. The purpose of this research study is to see if rosuvastatin lowers the
number of tissue factor bearing microparticles in the blood (TFMP). TFMP are small particles
that are generated from different types of blood cells in the body. In people who have
cancer, TFMP are thought to be generated from cancer cells and may represent a risk factor
for deep vein thrombosis.
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Dana-Farber Cancer Institute Massachusetts General Hospital National Institutes of Health (NIH)